Rex Bionics PLC Presentation of REX Case Report at SCI Conference

TIDMRXB

Rex Bionics PLC

18 November 2016

Rex Bionics Plc

("Rex Bionics" or the "Company")

Presentation of REX Case Report at Spinal Cord Injury Conference

   --     First evidence from multiple sessions of exercises with REX 
   --     Significant reduction in pain 

18th November 2016: Rex Bionics Plc (AIM: RXB), the pioneer of the REX Robot technology that enhances the mobility of wheelchair users, is pleased to announce the findings of a case report presented at the annual meeting of the Australian & New Zealand Spinal Cord Society, "ANZCoS", (Adelaide, Australia; 16-18 November, 2016).

Gilly Davy, Senior Neurological Physiotherapist and Clinical Director of Connect Neuro Physiotherapy, Auckland, New Zealand presented her evaluation of the practical clinical use of the REX, utilising the dynamic exercise treatment branded as "REXercises", by reference to a case report.

The participant, a 35-year-old male, had a complete T5 spinal cord injury from a traumatic accident in 2006. He has been living an independent lifestyle from his wheelchair since then but has suffered with chronic right shoulder, neck and thoracic spine pain with intermittent headaches for the past two years.

The participant completed once a week exercise regime in the REX over a 10 week period. The results demonstrated a significant improvement - with a complete resolution of headaches and neck pain and a significant reduction in shoulder and thoracic pain. The Numeric Pain Rating (NPR) scale improved significantly - with "current pain" reducing from 4/10 to 2/10 and "worst pain" reducing from 9/10 to 4/10.

Significant improvement was also recorded in The Goal Attainment Score (GAS) and the Canadian Occupational Performance Measure (COPM) - see "Further Data" below.

Up to 80% of people living with a spinal cord injury suffer from shoulder, neck and back pain.

Gilly Davy's presentation concluded "Standing, while completing upper body rehabilitation and strengthening in a stand-alone robotic exercise device, can significantly enhance neck and shoulder pain management and improve quality of life - highlighting that robotic exercise devices can offer a range of rehabilitation opportunities."

Crispin Simon, Chief Executive of Rex Bionics commented: "This case report is the first time that the results of a comprehensive, multi-week programme of REX treatment have been presented at a scientific conference; and is in line with the feedback that we get from patients - that exercising with REX can offer reduced pain and improved sleep."

A copy of this announcement has been posted on the Company's website at www.rexbionics.com/.

For further information please contact:

Rex Bionics Plc

Crispin Simon, Chief Executive Officer

[phone]

Peter Worrall, Chief Financial Officer

[phone]

Stifel Nicolaus Europe Limited (NOMAD and Broker)

Jonathan Senior/ Stewart Wallace / Ben Maddison

[phone]

Consilium Strategic Communications

Mary-Jane Elliott / Chris Welsh

[e-mail]

[phone]

Further Notes

The Goal Attainment Score uses a scale of -2 (deteriorated from base level), through 0 (goal achieved per expectations), to +2 (goal achieved above expectations). The following scores were recorded for the four goals. Reduce pain between the shoulders: +1; Reduce headaches: +2; Strengthen shoulders: 0; Improve sitting posture: 0.

The Canadian Occupational Performance Measured recorded achievement of the goal to "sleep through the night without waking up with pins and needles in arms and shoulders", on scales of satisfaction and performance with a maximum of 10 each. The score in this case report increased from 6 out of 20 (3 + 3), to 20 out of 20 (10 + 10).

Note: The Case Report participant is an employee of Rex Bionics.

About Rex Bionics Plc

Rex Bionics is the pioneer of the "REX" that provides robotic standing, walking and exercise support for wheelchair users; and was founded by two British engineers with first-hand experience of the needs of wheelchair users. REX is used by people who have suffered a spinal cord injury, stroke or other traumatic brain injury; and people with multiple sclerosis, muscular dystrophy and cerebral palsy.

We are working with physiotherapists to develop the concept and practice of Robot-Assisted Physiotherapy (RAP); and also offer REX P, for use in the home, enabling customers to walk and stand with their hands free - providing more work and recreation options.

Wheelchair users are at risk of developing numerous medical complications from extended periods of sitting. By enabling them to spend more time standing, walking and exercising, REX may offer significant health benefits, including improved sleep and maintenance of joint range, and a reduction in spasm, pain, common abdominal problems and prescription drug use.

Our commitment to engineering excellence is complemented by a commitment to clinical science and the RAPPER II clinical trial results show high levels of practicality, safety and user enthusiasm.

Our Vision is that every day, around the world, thousands of people get relief with REX, from the harm - the pain, discomfort and inconvenience - of neurological accidents and illnesses; and that many will be cured.

Rex Bionics was admitted to trading on the London Stock Exchange's AIM in 2014. REX is not registered for At-Home use in the United States of America.

Enquiries to ([e-mail])

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRALLFEDLVLDLIR

(END) Dow Jones Newswires

November 18, 2016 02:01 ET (07:01 GMT)